118947-86-7

Upstream product

• 2642-63-9 3',4'-dichloroacetophenone 
• 96605-05-9 C₁₁H₁₁Cl₂NO 
• 7357-70-2 Cyanothioacetamide 
• 118947-89-0 Sodium; (E)-3-(3,4-dichloro-phenyl)-3-oxo-propen-1-olate 
• 118947-83-4 (Z)-1-(3,4-Dichloro-phenyl)-3-piperidin-1-yl-propenone 

Downstream Products

• 1257317-78-4 3-amino-6-(3,4-dichlorophenyl)thieno[2,3-b]pyridine-2-carboxamide 
• 1288843-79-7 C₂₁H₁₄Cl₃N₃OS 
• 118947-91-4 2-Allylsulfanyl-6-(3,4-dichloro-phenyl)-nicotinonitrile 

Relevant academic research and scientific papers

Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors

Current treatment for hepatitis C is barely satisfactory, there is an urgent need to develop novel agents for combating hepatitis C virus infection. This study discovered a new class of thieno[2,3-b]pyridine derivatives as HCV inhibitors. First, a hit compound characterized by a thienopyridine core was identified in a cell-based screening of our privileged small molecule library. And then, structure activity relationship study of the hit compound led to the discovery of several potent compounds without obvious cytotoxicity in vitro (12c, EC50 = 3.3 μM, SI >30.3, 12b, EC50 = 3.5 μM, SI >28.6, 10l, EC50 = 3.9 μM, SI >25.6, 12o, EC 50 = 4.5 μM, SI >22.2, respectively). Although the mechanism of them had not been clearly elucidated, our preliminary optimization of this class of compounds had provided us a start point to develop new anti-HCV agents.

Facile synthesis of 6-aryl-3-cyanopyridine-2-(1H)-thiones from aryl ketones

An improved synthesis of 6-aryl-3-cyanopyridine-2-(1H)-thiones utilizing enaminones as starting materials catalyzed by 1,4-diazabicyclo[2.2.2]octane (DABCO) was described. Moreover, a convenient one-pot conversion of aryl ketones to 6-aryl-3-cyanopyridine-2-(1H)-thiones was also developed in moderate to good yields (up to 80%). Copyright Taylor & Francis Group, LLC.

Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: Synthesis, preliminary structure-activity relationships, and in vitro biological evaluation

Novel thienopyridine derivatives 1b-1r were synthesized, based on a hit compound 1a that was found in a previous cell-based screening of anticancer drugs. Compounds 1a-1r have the following features: (1) their anticancer activity in vitro was first reported by our group. (2) The most potent analog 1g possesses hepatocellular carcinoma (HCC)-specific anticancer activity. It can specifically inhibit the proliferation of the human hepatoma HepG2 cells with an IC50 value of 0.016 μM (compared with doxorubicin as a positive control, whose IC50 was 0.37 μM). It is inactive toward a panel of five different types of human cancer cell lines. (3) Compound 1g remarkably induces G0/G1 arrest and apoptosis in HepG2 cells in vitro at low micromolar concentrations. These results, especially the HCC-specific anticancer activity of 1g, suggest their potential in targeted chemotherapy for HCC.

CYCLIZATION REACTIONS OF NITRILS. 29. REGIOSELECTIVE SYNTHESIS OF 6-ARYL-3-CYANO-2(1H)-PYRIDINETHIONES AND THE CORRESPONDING SELENONES AND THEIR CHARACTERISTICS

The condensation of cyanothio- and cyanoselenoacetamide with 3-aryl-3-oxo-1-piperidino-1-propene or sodium 3-aryl-3-oxo-1-propen-1-olate takes place regioselectively with the formation of the 6-aryl-3-cyano-2(1H)-pyridinethiones or the corresponding selenones.Thienopyridines, thiazolopyridinium salts, and other annellated heterocycles were obtained from the 6-aryl-3-cyano-2(1H)-pyridinethiones.